Results
|
|
1.
|
Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors:
- Dilawari, Asma
- Gallagher, Christopher
- Khoury, Katia
- Lynce, Filipa
- Swain, Sandra M
Year: 2018
Department: - MedStar Georgetown University Hospital Residents
All authors: - Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F.
|
|
|
2.
|
Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors:
- Dilawari, Asma
- Gallagher, Christopher
- Khoury, Katia
- Lynce, Filipa
- Swain, Sandra M
Year: 2019
Department: - MedStar Georgetown University Hospital Residents
All authors: - Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F.
|
|
|
3.
|
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. MedStar authors:
- Blackburn, Matthew J
- Chitalia, Ami
- Dilawari, Asma
- Gallagher, Christopher
- Lynce, Filipa
- Mohebtash, Mahsa
- Tiwari, Shruti R
Year: 2021
Citation: - Cancer. 127(19):3622-3630, 2021 10 01.
Institution:
- MedStar Franklin Square Cancer Center at Loch Raven Campus
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department:
- Hematology & Oncology Fellowship
- Hematology and Oncology
Medline publication type:
All authors: - Abu-Khalaf M, Blackburn MJ, Chitalia A, Dilawari A, Gallagher C, Hahn OM, Isaacs C, Lynce F, Mohebtash M, Pohlmann PR, Shajahan-Haq AN, Tan M, Tiwari SR, Warren R, Wu T, Zhuo R
|
